Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Joy Wu is a board-certified endocrinologist who specializes in treating osteoporosis and other bone and mineral diseases, including primary hyperparathyroidism, vitamin D deficiency, Paget's disease and fibrous dysplasia. She has a special interest in optimizing skeletal health for those at risk of bone loss from glucocorticoid treatment, cancer therapies, or organ transplant. She works closely with each individual and his/her referring physician to assess fracture risk, and to develop a tailored treatment and monitoring plan. Dr Wu is Chief of the Division of Endocrinology, Gerontology and Metabolism and Vice Chair of Basic Science in the Department of Medicine at Stanford. She directs a broad basic and translational research program that focuses on skeletal development and the bone marrow hematopoietic niche. Her laboratory is currently studying stem cell therapies for bone formation, and the prevention of cancer metastases to bone (joywulab.stanford.edu). She has been honored with awards from the NIH Director’s New Innovator Award, the Endocrine Society, the American Society for Bone and Mineral Research, and the Mary Kay Foundation, and she has served on the Board of Directors for the Endocrine Society.
Osteoporosis, a disease of fragile bones resulting in fractures, will strike 50% of women and 25% of men. As a physician scientist, my laboratory is studying stem cells in the skeleton and bone marrow to develop novel regenerative approaches to increase bone quality and strength. We are also interested in how the skeleton supports hematopoiesis, and how diseases and medications that impact bone may affect blood cell production and cancer metastasis. For more detailed descriptions of ongoing research projects in the lab, visit our website at joywulab.stanford.edu.
Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients
Patients who undergo bone marrow transplant for different types of cancer are exposed to many
treatments such as steroids and whole body radiation. These treatments make the transplant
possible but also make their bones weaker and more prone to fractures which can be a source
of significant disability and decreased quality of life for cancer survivors. Our trial will
investigate whether giving one dose of Zoledronic acid (a commonly used drug given to
preserve bone mass in osteoporosis) before bone marrow transplant can protect from the bone
loss caused by the transplant procedures. The investigators are also interested in studying
the complex interactions of bone, muscle and fat which are greatly affected after bone marrow
Stanford is currently not accepting patients for this trial.
For more information, please contact Rodrigo Valderrabano, .
View full details